Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT00171808
- Locations
- 🇩🇪
Ebersberg, Germany, Hamburg, Germany
🇩🇪Novartis Investigative Site, Tuebingen, Germany
🇩🇪Tuebingen, Germany, Heidelberg, Germany
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00171730
- Locations
- 🇺🇸
NYU / VA Medical Center, New York, New York, United States
🇨🇭Novartis Investigative Site, Lausanne, Switzerland
🇺🇸Cedars Sinai Medical Center Dept. of Pituitary Ctr., Los Angeles, California, United States
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 293
- Registration Number
- NCT00171249
- Locations
- 🇺🇸
Dana Faber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
🇬🇧Novartis Investigative Site, London, United Kingdom
An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 260
- Registration Number
- NCT00171158
- Locations
- 🇺🇸
Dana Faber Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇮🇹Novartis Investigative Site, Monza, Italy
Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00170820
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT00171912
- Locations
- 🇦🇺
Novartis Investigative Site, East Melbourne, Australia
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2010-03-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 93
- Registration Number
- NCT00171847
- Locations
- 🇩🇪
Novartis Investigative Site, Tuebingen, Germany
The Use of Zoledronic Acid in Men on Androgen Deprivation Therapy for Prostate Cancer With Preexisting Osteoporosis
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT00171639
- Locations
- 🇺🇸
Southern AZ VA Health Care System, Tucson, Arizona, United States
🇺🇸Washington VA Medical Center, Washington, District of Columbia, United States
🇺🇸VA Medical Center-Long Beach, Long Beach, California, United States
Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 96
- Registration Number
- NCT00172068
- Locations
- 🇩🇪
Novartis Invstigative Site, Bielefeld, Germany
🇩🇪Novartis Investigative Site, Tuebingen, Germany
Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT00170911